Condition: Lymphoma · Sponsor: Treeline Biosciences, Inc.
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
This description comes directly from the study's public registry record.
Treeline Clinical Operations · 857-228-0050 · clinicaloperations@treeline.bio
Always discuss trial participation with your own doctor first.
| Stanford Cancer Institute | Stanford, California, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| British Columbia Cancer Agency | Vancouver, British Columbia, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06733441